Work

Comparative Assessment of Sunitinib-Associated Adverse Events (AES) as Potential Biomarkers of Efficacy in Metastatic Renal Cell Carcinoma (MRCC)

Year: 2012

Type: article

Source: Annals of Oncology

DOI: 10.1016/s0923-7534(20)33370-6

Authors: F. Donskov, M.D. Michaelson, I. Puzanov, M.P. Davis, G.A. Bjarnason, R.J. Motzer, X. Lin, D.P. Cohen, R. Wiltshire, B.I. Rini

Institutions: Aarhus University Hospital, Massachusetts General Hospital, Vanderbilt University, Vanderbilt University Medical Center, Cleveland Clinic, Sunnybrook Health Science Centre, Odette Cancer Centre, Memorial Sloan Kettering Cancer Center, Pfizer (United States), Pfizer (United Kingdom)

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W3006944388

FWCI: 2.377

Cites:

Cited by: 12

Related to: 10